Nevirapine Reassessed by the WHO as the Preferred Drug to Prevent Mother-to-child Transmission of HIV
Nevirapine Reassessed by the WHO as the Preferred Drug to Prevent Mother-to-child Transmission of HIV
Pablo Barreiro
Department of Infectious Diseases, Hospital Carlos III-La Paz University Hospital. Madrid, Spain
*Correspondence: Pablo Barreiro, Email not available
Abstract
The Division of AIDS of the National Institutes ofHealth (NIH) in Bethesda has recently releasedthe final report (dated March 2003) from thereassessment of the trial procedures and resultsin the HIVNET 012 trial conducted in Uganda(www.niaid.nih.gov/daids/Prevention.htm). This trial,the first to demonstrate the safety and efficacyof nevirapine (NVP) to prevent mother-to-childtransmission (MTCT) of HIV, was started inUganda in 1997 and the results were publishedin 1999 (Guay, et al. Lancet 1999;354:795-802).
